Literature DB >> 29780705

No room for statins in the quest for survival benefits in small cell lung cancer.

Francesco Facchinetti1, Marcello Tiseo1.   

Abstract

Entities:  

Year:  2018        PMID： 29780705      PMCID： PMC5943234          DOI： 10.21037/tlcr.2018.03.07

Source DB:  PubMed          Journal:  Transl Lung Cancer Res        ISSN： 2218-6751


× No keyword cloud information.
  16 in total

Review 1.  Targeting RAS Membrane Association: Back to the Future for Anti-RAS Drug Discovery?

Authors:  Adrienne D Cox; Channing J Der; Mark R Philips
Journal:  Clin Cancer Res       Date:  2015-04-15       Impact factor: 12.531

2.  Statin use and reduced cancer-related mortality.

Authors:  Sune F Nielsen; Børge G Nordestgaard; Stig E Bojesen
Journal:  N Engl J Med       Date:  2012-11-08       Impact factor: 91.245

Review 3.  Implications of farnesyltransferase and its inhibitors as a promising strategy for cancer therapy.

Authors:  Sergey G Klochkov; Margarita E Neganova; Nagendra Sastry Yarla; Madhukiran Parvathaneni; Bechan Sharma; Vadim V Tarasov; George Barreto; Sergey O Bachurin; Ghulam Md Ashraf; Gjumrakch Aliev
Journal:  Semin Cancer Biol       Date:  2017-10-31       Impact factor: 15.707

Review 4.  Precision Diagnosis and Treatment for Advanced Non-Small-Cell Lung Cancer.

Authors:  Martin Reck; Klaus F Rabe
Journal:  N Engl J Med       Date:  2017-08-31       Impact factor: 91.245

Review 5.  Statin use and mortality in cancer patients: Systematic review and meta-analysis of observational studies.

Authors:  Shanliang Zhong; Xiaohui Zhang; Lin Chen; Tengfei Ma; Jinhai Tang; Jianhua Zhao
Journal:  Cancer Treat Rev       Date:  2015-04-11       Impact factor: 12.111

6.  Potent inhibition of small-cell lung cancer cell growth by simvastatin reveals selective functions of Ras isoforms in growth factor signalling.

Authors:  U K Khanzada; O E Pardo; C Meier; J Downward; M J Seckl; A Arcaro
Journal:  Oncogene       Date:  2006-02-09       Impact factor: 9.867

Review 7.  Long-Term Effectiveness and Safety of Pravastatin in Patients With Coronary Heart Disease: Sixteen Years of Follow-Up of the LIPID Study.

Authors:  Wendy E Hague; John Simes; Adrienne Kirby; Anthony C Keech; Harvey D White; David Hunt; Paul J Nestel; David M Colquhoun; Helen Pater; Ralph A Stewart; David R Sullivan; Peter L Thompson; Malcolm West; Paul P Glasziou; Andrew M Tonkin
Journal:  Circulation       Date:  2016-03-25       Impact factor: 29.690

8.  Selumetinib Plus Docetaxel Compared With Docetaxel Alone and Progression-Free Survival in Patients With KRAS-Mutant Advanced Non-Small Cell Lung Cancer: The SELECT-1 Randomized Clinical Trial.

Authors:  Pasi A Jänne; Michel M van den Heuvel; Fabrice Barlesi; Manuel Cobo; Julien Mazieres; Lucio Crinò; Sergey Orlov; Fiona Blackhall; Juergen Wolf; Pilar Garrido; Artem Poltoratskiy; Gabriella Mariani; Dana Ghiorghiu; Elaine Kilgour; Paul Smith; Alexander Kohlmann; David J Carlile; David Lawrence; Karin Bowen; Johan Vansteenkiste
Journal:  JAMA       Date:  2017-05-09       Impact factor: 56.272

9.  Anti-angiogenic therapy using thalidomide combined with chemotherapy in small cell lung cancer: a randomized, double-blind, placebo-controlled trial.

Authors:  Siow Ming Lee; Penella J Woll; Robin Rudd; David Ferry; Mary O'Brien; Gary Middleton; Stephen Spiro; Lindsay James; Kulsam Ali; Mark Jitlal; Allan Hackshaw
Journal:  J Natl Cancer Inst       Date:  2009-07-16       Impact factor: 13.506

10.  Multicenter, Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Pravastatin Added to First-Line Standard Chemotherapy in Small-Cell Lung Cancer (LUNGSTAR).

Authors:  Michael J Seckl; Christian H Ottensmeier; Michael Cullen; Peter Schmid; Yenting Ngai; Dakshinamoorthy Muthukumar; Joyce Thompson; Susan Harden; Gary Middleton; Kate M Fife; Barbara Crosse; Paul Taylor; Stephen Nash; Allan Hackshaw
Journal:  J Clin Oncol       Date:  2017-02-27       Impact factor: 44.544
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.